Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital

Group 1 - Analyst Jason Kolbert from D. Boral Capital raised the price target on Quince Therapeutics (QNCX) to $5 from $4, maintaining a Buy rating on the shares [1] - The increase in the price target follows the completion of the last patient visit in the pivotal Phase 3 NEAT clinical trial for encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia [1] - The firm attributes the target increase to the rolling of its valuation metrics out a year [1]